Sunovion Pharmaceuticals Inc.’s patent (number 9,174,975) for Lurasidone Hydrochloride is set to expire on August 20, 2024. For related pharmaceutical business intelligence, contact DrugPatentWatch.

GP2GP likely to be phased out and more briefs
Te Whatu Ora plans to address risks of the outdated GP2GP electronic record system until a new digital health record launches midyear. In Western Australia,